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Despite the introduction of targeted therapies in pediatric pulmonary arterial hyper-
tension (PAH), prognosis remains poor. For the definition of treatment strategies and 
guidelines, there is a high need for an evidence-based recapitulation of prognostic 
factors. The aim of this study was to identify and evaluate prognostic factors in pediatric 
PAH by a systematic review of the literature and to summarize the prognostic value of 
currently reported prognostic factors using meta-analysis.
Methods and results
Medline, EMBASE and Cochrane Library were searched on April 1st 2014 to identify origi-
nal studies that described predictors of mortality or lung-transplantation exclusively in 
children with PAH. 1053 citations were identified, of which 25 were included for further 
analysis. Hazard ratios (HR) and 95% confidence intervals were extracted from the pa-
pers. For variables studied in at least three non-overlapping cohorts, a combined HR was 
calculated using random-effects meta-analysis. WHO functional class (WHO-FC, HR 2.7), 
(N-terminal pro) brain natriuretic peptide ([NT-pro]BNP, HR 3.2), mean right atrial pres-
sure (mRAP, HR 1.1), cardiac index (HR 0.7), indexed pulmonary vascular resistance (PVRi, 
HR 1.3) and acute vasodilator response (HR 0.3) were identified as significant prognostic 
factors (p≤0.001).
Conclusions
This systematic review combined with separate meta-analyses shows that WHO-FC, 
(NT-pro)BNP, mRAP, PVRi, cardiac index and acute vasodilator response are consistently 
reported prognostic factors for outcome in pediatric PAH. These variables are useful 
clinical tools to assess prognosis and should be incorporated in treatment strategies 
and guidelines for children with PAH.
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IntroduCtIon
Pulmonary arterial hypertension (PAH) is a severe progressive disease of the pulmonary 
vasculature, leading to increased pulmonary vascular resistance (PVR), right ventricular 
(RV) failure and death.1 Since the recent introduction of specific PAH-targeted drugs, 
quality of life and survival in both children and adults have improved, but remain unsat-
isfactory.2-4
For clinical decision-making in the treatment of these patients, it is important to 
be able to predict survival using prognostic factors.5 In adults with idiopathic PAH, vari-
ous prognostic factors have been identified and reviewed.6,7 Although data in children 
are limited, several pediatric studies have recently reported on survival and prognostic 
factors. These data, however, are mostly derived from relatively small patient series and 
contradictory findings have been reported. It is unclear whether contradictions that 
have emerged from recent pediatric studies can be explained by differences in study 
populations, different treatment strategies or by insufficient power of the individual 
studies due to small sample sizes.
There is a high clinical need to improve treatment strategies and to define guide-
lines for the management of children with PAH. Therefore, it is of great importance to 
identify, appraise, synthesize and combine the currently available data on prognostic 
factors in pediatric PAH. This will help in defining current evidence and in developing 
supportive guidelines for the management of infants and children with PAH. Hence, the 
aim of this study was to identify and evaluate prognostic factors in pediatric PAH, by a 
systematic review of the literature and to subsequently summarize the prognostic value 
of currently reported prognostic factors in children with PAH using meta-analysis.
Methods
literature search
Medline, EMBASE and Cochrane Library were searched on April 1st 2014. The initial 
literature search focused on the overlapping part of three elements: (1) PAH, (2) children 
and (3) survival. To achieve this, a search string was composed and adapted to the 
three literature databases (Supplementary Table 1). The keyword “primary pulmonary 
hypertension” was also included, as this term was previously used for idiopathic PAH 
(IPAH). In contrast, the formerly used term “secondary pulmonary hypertension” for PH 
other than IPAH was not included because this group also comprised forms of PH with 
different etiologies and disease mechanisms than PAH. The search was limited to human 
studies and English language. The reference lists of all primary identified articles were 
hand searched for additional relevant publications.
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study selection
Titles and abstracts were screened by two independent reviewers (M.J.P and W.M.H.Z., 
investigators) to identify studies that described predictors of mortality in children with 
PAH. Eligible studies were required to report at least (1) data on mortality in pediatric 
PAH and (2) variables studied in relation to mortality. Studies were considered ineligible 
if they were animal studies or review articles, were not limited to children or when no 
survival analysis (Cox regression analysis or Kaplan-Meier survival analysis) was per-
formed. All remaining studies underwent full-text review, with a targeted focus on the 
study population and survival analysis details. Studies were excluded when >20% of the 
study population did not meet the current PAH definition according to the updated Nice 
classification.8 Studies using endpoints other than death or death + lung-transplantation 
were also excluded. Any disagreements between the reviewers were resolved by discus-
sion leading to consensus or by consulting a third-party arbitrator (H.L.H., epidemiolo-
gist/statistical consultant).
data extraction
Of all studied variables, hazard ratios (HR) and 95% confidence intervals (CI) derived from 
univariable Cox regression analysis were extracted from the papers. When the CI was not 
reported, the P-value was used to estimate the CI.9 When only Kaplan-Meier analysis was 
performed to assess a variable’s relation with survival, HR and CI were estimated using 
Parmar’s survival curve method, on the condition that picture quality and description 
of patient numbers were sufficient.10 When individual patient data were provided in the 
paper in the absence of a reported HR, the HR and CI were calculated using Cox regres-
sion analysis rather than estimated from the survival curve. When the HR was described 
for death and death + lung-transplantation, the HR for death was extracted. When analy-
ses were performed for characteristics at different baseline moments (e.g. both time of 
diagnosis and study enrollment), the baseline with least missing values was used.
data synthesis
Multiple separate random-effects meta-analyses were conducted to calculate combined 
HRs for sufficiently studied candidate prognostic factors. The following methodological 
considerations were taken into account: (1) patient-overlap between studies, (2) suf-
ficiency of number of combinable studies, (3) differences in how the HR was calculated 
and (4) potential between-study heterogeneity.
Patient-overlap between studies is likely to exist, since most studies on pediatric 
PAH are performed in a limited number of centers. When a variable was studied and 
reported more than once by the same center with overlapping inclusion-periods, only 
the HR from the largest study was included in the meta-analysis. In the case of exactly 
matching patient numbers, the most recent study was included. HRs from studies that 
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combined previously published cohorts in a new individual patient data level analysis 
were excluded, unless a HR was not available from the original cohort studies. The HRs 
of all excluded studies were still displayed in the meta-analysis forest plots in a different 
color to retain overview of the entirety and consistency of the available data.
Meta-analysis was only considered appropriate when a candidate prognostic fac-
tor was studied in at least three non-overlapping cohorts. When meta-analysis was not 
appropriate, results were summarized in tabular form.
Differences in how the HR was calculated, such as variation in the number of 
units change used for HR calculation (e.g. when one study reported the HR per 1 mmHg 
pressure change while another reported the HR per 5 mmHg change), were addressed 
by recalculating the HRs using a uniform clinically applicable number of units change. 
HRs of dichotomized continuous variables (i.e. when patients with high values were 
compared to patients with low values), could not be recalculated and were left unad-
justed. HRs based on dichotomized variables were not combined with HRs based on 
continuous variables, but were displayed separately. The choice of including HRs based 
on dichotomized or continuous variables in meta-analyses depended on how often 
the methods were applied: studies with the least applied method were excluded from 
the meta-analysis but were still displayed in the forest plot in a different color to retain 
overview of the entirety and consistency of the available data.
Heterogeneity was assessed using both Cochran’s Q-test and the I2 quantity. In 
view of the small number of studies to be compared, a Q-test p-value <0.10 or an I2 
quantity >50% were considered indicative of substantial heterogeneity. In the case of a 
statistically significant combined weighted HR in combination with substantial evidence 
for heterogeneity, the methodological characteristics and study populations were 
compared and exploratory sub-group analysis and meta-regression were conducted to 
identify potential causes of heterogeneity. Analyses were performed using STATA 11.0 




In total, 1053 citations were identified (Figure 1). With screening titles and abstracts, 989 
citations were excluded, leaving 64 articles for full-text review (references are provided 
as Supplementary Material). Screening full articles identified 27 articles that described 
prognostic factors for survival exclusively in pediatric PAH (Supplementary Table 2). 
Exclusion reasons per publication are shown in Supplementary Table 3. Additionally, 
two primarily identified studies were excluded from further data analysis because of 
inconsistency in data reporting within the paper,11 and because of demonstrable 100% 
patient-overlap with a previously published report.12 The main characteristics of the 
remaining 25 studies are outlined in Table 1.
1053 unique publications 
identified 
64 full text review 
989 publications excluded during abstract review 
 
148 Not English 
  13 Animal studies 
308 Not original article 
  87  Case reports 
110 PH not main topic 
250 Not paediatric study 
  73 No described survival 
25 publications eligible for 
inclusion 
40 publications excluded during full text review 
  6     PAH not main topic (PH group 1, Nice classification) 
  4     Not paediatric study or analysis not restricted to children 
  1     No described survival 
24     No survival analysis performeda 
  3     Endpoint other than death or death + transplantation 
  2     Other reasonsb 
 
1 publication added during reference list hand search 
14/25 HR and CI reported in paper 
 
1/11 HR and CI 
lacking, individual 
patient data in paper  
Reported HR and CI used in 
meta-analysis 
746 MEDLINE 705 EMBASE 9 The Cochrane Library 
2/11 HR and  
P-value available,  
CI lacking 
Calculated HR and CI used in 
meta-analysis 
CI estimated using P-valuec HR and CI estimated using 
Parmar’s survival curve methodd 
Exact HR and CI calculated 
using Cox regression analysis 
8/11 HR and CI 
lacking, Survival 
curves available 
Reported HR and estimated CI 
used in meta-analysis 
Estimated HR and CI used in 
meta-analysis 
11/25 HR and / or CI not reported in paper 
 
Figure 1. Flow chart showing study selection and data extraction. PH = pulmonary hypertension; PAH 
= pulmonary arterial hypertension; HR = hazard ratio; CI = 95% confidence interval. aSurvival analysis in 
which a candidate prognostic factor is evaluated using Cox regression analysis or Kaplan Meier analysis 
(not: comparison of treatment group survival). bOther reasons included: inconsistency in data reporting 
within the paper and demonstrable 100% patient overlap with another included paper. cSee Altman et al. 
2011 [9]. dSeeParmar et al. 1998 [10].




























Type of survival analysis
Endpoint
IPAH / HPAH / Primary PH (%)
APAH-CHD (%)
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Identified candidate prognostic factors
Table 2 summarizes a total of 40 variables that have been shown to be significantly re-
lated to survival in one or more studies. The availability of HRs (either directly reported or 
indirectly calculable) is also shown in Table 2. For 10 of the 40 identified variables, there 
were HRs available from at least three non-overlapping cohorts. For these 10 candidate 
prognostic factors, a combined HR and accompanying P-value could be calculated using 
meta-analysis (Table 3). The corresponding forest plots are displayed in Figures 2-4. The 
meta-analysis results of the 10 candidate prognostic factors are detailed below.
Age was investigated in 10 studies, with HRs available from 6/10 studies (Table 2). One 
of these 6 was omitted from meta-analysis to prevent duplicate patient inclusion (Figure 
2).13 Combining the remaining 5 non-overlapping cohorts representing 426 patients 
yielded a HR (CI) of 1.01 (0.92-1.10) per year increase (Figure 2, p=0.866), indicating no 
significant association with survival. North-American studies (Sandoval, Barst 1999, 
Barst 2012 and Wagner13-16) and European studies (Moledina and Douwes17,18) reported 
contradictory findings.
table 3. Combined Prognostic Value of Candidate Prognostic Factors
Predictor N HR (CI) P-value
demographic
Age, per year 426 1.01 (0.92-1.10) 0.866
Sex, male compared to female 428 1.38 (0.55-3.43) 0.495
Clinical / biochemical
Diagnosis, APAH compared to IPAH 585 0.70 (0.41-1.19) 0.191
WHO-FC (high compared to low) 307 2.67 (1.49-4.80) 0.001
(NT-pro)BNP (high compared to low) 351 3.24 (1.76-6.02) <0.001
hemodynamic
mRAP, per mmHg 404 1.12 (1.05-1.20) 0.001
mPAP, per 10 mmHg 254 1.18 (0.99-1.40) 0.056
Cardiac index, per 1 L/min/m2 360 0.66 (0.52-0.84) 0.001
PVRi, per 10 WU*m2 353 1.32 (1.17-1.48) <0.001
Acute vasodilator response 312 0.27 (0.14-0.54) <0.001
Data is presented as hazard ratio (95% confidence interval). HR = hazard ratio; CI = 95% confidence interval; 
APAH = associated pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; WHO-
FC = WHO functional class; (NT-pro)BNP = (N-terminal-pro) brain natriuretic peptide; mRAP = mean right atrial 
pressure; mPAP = mean pulmonary arterial pressure; PVRi = (indexed) pulmonary vascular resistance; WU = 
wood units.
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Sex was investigated in 10 studies, with HRs available from 5/10 studies (Table 2). 
Combining these 5 non-overlapping cohorts representing 428 patients yielded a HR 
(CI) of 1.38 (0.55-3.43) for male compared to female (Figure 2, p=0.495), indicating no 
significant association with survival.
Diagnosis was investigated in 9 studies, with HRs available from 2 studies and 
survival curves available from 5 studies (Table 2). Four of these 7 were omitted from 
meta-analysis to prevent duplicate patient inclusion (Figure 3).3,4,18,19 Combining the 
remaining 3 non-overlapping cohorts representing 585 patients yielded a HR (CI) of 0.70 
(0.41-1.19) for associated PAH (APAH) compared to IPAH (Figure 3, p=0.191), indicating 
no significant association with survival.
World Health Organization functional class (WHO-FC) was investigated in 11 stud-
ies, with HRs available from 10/11 studies (Table 2). Since WHO-FC was mostly studied as 
a dichotomized variable, 3 studies that reported HRs based on WHO-FC as a continuous 
variable were omitted from meta-analysis (Figure 3).3,17,20 An additional 3 studies were 
omitted to prevent duplicate patient inclusion.4,13,21Combining the remaining 4 non-
overlapping cohorts representing 307 patients yielded a HR (CI) of 2.67 (1.49-4.80), for 
high compared to low WHO-FC (Figure 3, p=0.001), without substantial heterogeneity-
evidence (p=0.452, I2=0.0%).
HR per year increase 
Sandoval 1995, n=18 
Barst 1999, n=77 
Moledina 2010, n=64 
Barst 2012, n=215 
Douwes 2013, n=52 
Wagner 2013, n=83 
COMBINED, n=426 (p=0.866) 
Heterogeneity: p=0.011, I2=69.5% 
Age 
HR of male compared to female 
Sandoval 1995, n=18 
Barst 1999, n=77 
Moledina 2010, n=64 
Barst 2012, n=215 
Chida 2012, n=54 
COMBINED, n=428 (p=0.495) 
Heterogeneity: p=0.019, I2=66.0% 
Sex 








HR (95% CI) 






      0.67                   1                     1.5 
      0.05                    1                      20 
1
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2 00 . 0 5
Figure 2. Forest plots showing demographic candidate prognostic factors. HR = hazard ratio; CI = confi-
dence interval. HRs displayed as diamonds ◆ are based on dichotomized variables, HR’s displayed as dots 
● are based on continuous variables. Area of each diamond / dot is proportional to the sample size of the 
studied cohort. Only HRs in blue are non-overlapping and included in meta-analysis.
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HR of high compared to low WHO-FC or per FC increase 
Sandoval 1995, n=18 (III/IV vs. I/II) 
Van Loon 2010, n=52 (per FC) 
Lammers 2010, n=47 (III/IV vs. I/II) 
Moledina 2010, n=64 (per FC) 
Ivy 2010, n=81 (III/IV vs. I/II) 
Moledina 2011, n=31 (per FC) 
Barst 2012, n=190 (III/IV vs. I/II) 
Douwes 2013, n=52 (IV vs. I/II/III) 
Wagner 2013, n=83 (III/IV vs. I/II) 
Zijlstra 2014, n=236 (III/IV vs. I/II) 
COMBINED, n=307 (p=0.001) 
Heterogeneity: p=0.452, I2=0.0% 












HR of high compared to low (NT-pro)-BNP or per unit increase 
Nakayma 2007, n=27 (400 pg/mL)a,d 
Van Albada 2008, n=24 (per ng/mL)b,e 
Bernus 2009, n=78 (180 pg/mL)a,d 
Lammers 2009, n=50 (130 pg/mL)a,d 
Van Loon 2010, n=52 (per 10-Log value)e 
Barst 2012, n=215 (50/[300] pg/mL)f 
Chida 2014, n=59 (537 pg/mL)e 
Zijlstra 2014, n=41 (per 10-Log value)e 
COMBINED, n=351 (p<0.001) 
Heterogeneity: p=0.664, I2=0.0% 
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HR of APAH compared to IPAH 
Haworth 2009, n=216a 
Van Loon 2010, n=52a 
Hislop 2011, n=101a 
Van Loon 2011, n=154a 
Barst 2012, n=215 
Douwes 2013, n=52a 
Zijlstra 2014, n=275 
COMBINED, n=585 (p=0.191) 
Heterogeneity: p=0.108, I2=55.1% 
Diagnosis 
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Figure 3. Forest plots showing clinical and biochemical candidate prognostic factors. HR = hazard ratio; 
CI = confidence interval; APAH = associated pulmonary arterial hypertension; IPAH = idiopathic pulmonary 
arterial hypertension; FC = functional class; (NT-pro)BNP = (N-terminal-pro) brain natriuretic peptide. HRs 
displayed as diamonds ◆ are based on dichotomized variables, HRs displayed as dots ● are based on con-
tinuous variables. Area of each diamond / dot is proportional to the sample size of the studied cohort. Only 
HRs in blue are non-overlapping and included in meta-analysis. aHR estimated from survival curve. bHR 
calculated from reported individual patient data. cBetween brackets are the cut-off values used in dichoto-
mization or the number of units increase at which the HR calculation was based. dStudied biomarker was 
BNP. eStudied biomarker was NT-proBNP. fBoth BNP and NT-proBNP were studied.
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(N-Terminal-pro) brain natriuretic peptide ([NT-pro]BNP) was investigated in 9 stud-
ies (Table 2, 4x BNP, 3x NT-proBNP, 2x both) and the results of these studies were com-
bined. HRs, survival curves and individual patient data were available from 4, 3 and 1 
studies, respectively (Figure 3). Since (NT-pro)BNP was mostly studied as a dichotomized 
HR per 1 mmHg increase in mRAP 
Sandoval 1995, n=18 (>7 mmHg)b 
Clabby 1997, n=50 
Barst 1999, n=77 
Lammers 2010, n=47 
Moledina 2010, n=58 
Zijlstra 2014, n=269 
COMBINED, n=404 (p=0.001) 
Heterogeneity: p=0.289, I2=19.3% 








HR per 10 mm Hg increase 
Sandoval 1995, n=18 (>66 mmHg) 
Clabby 1997, n=50 
Barst 1999, n=77 
Lammers 2010, n=47 
Moledina 2010, n=58 
Douwes 2013, n=52 
Wagner 2013, n=67 
COMBINED, n=254 (p=0.056) 
Heterogeneity: p=0.189, I2=37.2% 









HR per 10 WU.m2 increase in indexed PVR 
Sandoval 1995, n=18 (>23 WU.m2) 
Clabby 1997, n=50 
Barst 1999, n=77 
Lammers 2010, n=47 
Moledina 2010, n=58 
Ivy 2010, n=66 (>20 WU.m2) 
Barst 2012, n=166 
Douwes 2013, n=52 
Wagner 2013, n=67 
Zijlstra 2014, n=275 
COMBINED, n=353 (p<0.001) 
Heterogeneity: p=0.731, I2=0.0% 












HR of responders compared to non-responders 
Sandoval 1995, n=18c 
Barst 1999, n=77d 
Barst 2012, n=174e 
Apitz 2012, n=43f,g 
COMBINED, n=312 (p<0.001) 
Heterogeneity: p=0.801, I2=0.0%) 






HR per 1 L/min/m2 increase 
Sandoval 1995, n=18 (>3 L/min/m2) 
Barst 1999, n=77 
Van Loon 2010, n=52 
Moledina 2010, n=58 
Barst 2012, n=173 
Douwes 2013, n=52 
Zijlstra 2014, n=270 
COMBINED, n=360 (p=0.001) 
Heterogeneity: p=0.685, I2=0.0% 













Responsiveness To Acute Vasodilator Testing 
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Figure 4. Forest plots showing hemodynamic candidate prognostic factors. mRAP = mean right atrial pres-
sure; HR = hazard ratio; CI = confidence interval; mPAP = mean pulmonary artery pressure; PVRi = indexed 
pulmonary vascular resistance; WU = wood units. HRs displayed as diamonds ◊ are based on dichotomized 
variables, HRs displayed as dots • are based on continuous variables. Area of each diamond / dot is pro-
portional to the sample size of the studied cohort. Only HRs in blue are non-overlapping and included in 
meta-analysis. aBetween brackets are the cut-off values used in dichotomization of the variable at which 
the HR calculation was based. bBecause of the high HR and wide 95% CI, this study is shown on a different 
scale. cResponse defined as (1) >20% decrease in mPAP or PVRi, (2) decrease in pulmonary / systemic vascu-
lar resistance ratio and (3) absence of a deleterious effect on pulmonary gas exchange. dResponse defined 
as (1) ≥20% decrease in mPAP, (2) no decrease in cardiac index and (3) no increase in pulmonary / systemic 
vascular resistance ratio. eResponse defined as (1) ≥20% decrease in mPAP, (2) no decrease in cardiac index 
<2.5 L/min/m2 and (3) no increase in pulmonary / systemic vascular resistance ratio. fResponse defined as 
>20% reduction of mean pulmonary artery pressure / mean systemic artery pressure ratio. gHR estimated 
from survival curve.
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variable, 3 studies that reported HRs based on (NT-pro)BNP as a continuous variable were 
omitted from meta-analysis.3,4,22 One additional study was omitted to prevent duplicate 
patient inclusion.23 Combining the 4 remaining non-overlapping cohorts representing 
351 patients yielded a HR (CI) of 3.24 (1.76-6.02) for high levels compared to low (Figure 
3, p<0.001), without substantial heterogeneity-evidence (p=0.664, I2=0.0%).
To be able to selectively analyze BNP instead of analyzing BNP and NT-proBNP 
together, we performed a sensitivity analysis. In the studies of Nakayama et al., Bernus 
et al., and Lammers et al., BNP was studied exclusively.23-25 Combining these 3 non-
overlapping cohorts representing 155 patients yielded a HR (CI) of 4.24 (1.80-9.96) for 
high levels compared to low (Supplementary Figure 1, p=0.001), without substantial 
heterogeneity-evidence (p=0.284, I2=20.5%). A similar separate analysis for NT-proBNP 
was hampered by the low number of non-overlapping cohorts in which NT-proBNP was 
studied exclusively (n=2).
Mean right atrial pressure (mRAP) was investigated in 9 studies, with HRs available 
from 6/9 studies (Table 2). Since mRAP was mostly studied as a continuous variable, 1 
study that reported a HR based on dichotomized mRAP was omitted from meta-analysis 
(Figure 4).14 An additional 2 studies were omitted to prevent duplicate patient inclu-
sion.26,27 Combining the remaining 3 non-overlapping cohorts representing 404 patients 
yielded a HR (CI) of 1.12 (1.05-1.20) per mmHg increase (Figure 4, p=0.001), without 
substantial heterogeneity-evidence (p=0.289, I2=19.3%).
Mean pulmonary artery pressure (mPAP) was investigated in 11 studies, with HRs 
available from 7/11 studies (Table 2). Since mPAP was mostly studied as a continuous 
variable, 1 study that reported a HR based on dichotomized mPAP was omitted from 
meta-analysis (Figure 4).14 An additional 2 studies were omitted to prevent duplicate 
patient inclusion.26,27 Combining the remaining 4 non-overlapping cohorts representing 
254 patients yielded a HR (CI) of 1.18 (0.99-1.40) per mmHg increase (Figure 4, p=0.056), 
indicating no significant association with survival.
Cardiac index was investigated in 10 studies, with HRs available in 7/10 studies 
(Table 2). Since cardiac index was mostly studied as a continuous variable, 1 study that 
reported a HR based on dichotomized cardiac index was omitted from meta-analysis 
(Figure 4).14 An additional 2 studies were omitted to prevent duplicate patient inclu-
sion.3,4 Combining the remaining 4 non-overlapping cohorts representing 360 patients 
yielded a HR (CI) of 0.66 (0.52-0.84) per L/min/m2 increase (Figure 4, p=0.001), without 
substantial heterogeneity-evidence (p=0.685, I2=0.0%).
Indexed pulmonary vascular resistance (PVRi) was investigated in 12 studies, with 
HRs available in 10/12 studies (Table 2). Since PVRi was mostly studied as a continuous 
variable, 2 studies that reported a HR based on dichotomized PVRi were omitted from 
meta-analysis (Figure 4).14,21 An additional 4 studies were omitted to prevent duplicate 
patient inclusion.4,13,26,27 Combining the remaining 4 non-overlapping cohorts represent-
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ing 353 patients yielded a HR (CI) of 1.32 (1.17-1.48) per 10 WU*m2 increase (Figure 4, 
p<0.001), without substantial heterogeneity-evidence (p=0.731, I2=0.0%).
Acute vasodilator response was investigated in 7 studies, with HRs and survival 
curves available from 3 and 1 studies, respectively (Table 2). It must be noted that the 
used vasodilators and definitions of a favorable response differed in these studies 
(Figure 4). Still, combining these 4 non-overlapping cohorts representing 312 patients 
yielded a HR (CI) of 0.27 (0.14-0.45) for responders compared to non-responders (Figure 
4, p<0.001), without substantial heterogeneity-evidence (p=0.801, I2=0.0%).
Other variables. Table 2 shows that imaging modalities have also been studied 
more than once (5x echocardiography, 1x cardiac magnetic resonance imaging [CMR]). 
None of the investigated echo-variables has been studied more than once in the same 
way, hampering further comparison or meta-analysis.
dIsCussIon
To our knowledge, this is the first study systematically reviewing and meta-analyzing 
all currently available prognostic factors in pediatric PAH. Separate meta-analyses for 
candidate prognostic factors showed convincing evidence for the prognostic value of 
the following six variables: WHO-FC, (NT-pro)BNP, mRAP, PVRi, cardiac index and acute 
vasodilator response.
Systematic reviews combined with meta-analyses are powerful methods for sum-
marizing and synthesizing data and are the building blocks of evidence-based practice. 
The highest level of evidence is reached when only randomized studies are included in 
a systematic review, but the available systematic reviews in adults show that this is not 
possible in a rare disease like PAH.6,28 As stated by the Cochrane Collaboration, a system-
atic review of non-randomized observational studies is justified when the question of 
interest cannot be answered by a review of randomized trials.29 As only one randomized 
trial has been performed in children with PAH, this justification especially applies to the 
field of pediatric PAH.30,31
Prognostic factors have also been systematically reviewed in adult PAH.6,7,28 Well-
established predictors of mortality in adults include: WHO-FC, heart rate, 6-minute walk 
distance (6MWD), (NT-pro)BNP, pericardial effusion, tricuspid annular plane systolic 
excursion, mPAP, mRAP, cardiac index, stroke volume index, PVR, acute vasodilator re-
sponse and mixed venous oxygen saturations. The six prognostic factors identified in the 
current study are highly in line with adult evidence. However, an important difference 
between adult and pediatric PAH is the available evidence for 6MWD as a prognostic 
factor. Whereas 6MWD has repeatedly and consistently been shown to predict survival 
in adults2,32, the prognostic value of 6MWD in children has been questioned because of 
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its limited feasibility at young age and the lack of available data (Table 2). More pediatric 
research is needed on this topic, and might focus on the prognostic value of 6MWD in 
older children (e.g. ≥7 years).
Several recommendations regarding the clinical assessment of prognosis have 
been made in current adult treatment guidelines.5 Since the results from the current 
systematic review provide an overview of evidence for prognostic factors specifically in 
pediatric PAH, such recommendations are now also possible for children.
Prognostic factors with moderate to high level of evidence
WHO-FC. The applicability of WHO-FC in young children has been questioned in the past, 
because it is mainly based on the observation and impression of caregivers. Despite 
this apparent limitation, the current study shows WHO-FC to be one of the strongest 
prognostic factors in pediatric PAH, also in the relatively younger pediatric cohorts. Not 
all studies on WHO-FC could be included in meta-analysis because of potential patient 
overlap, but combining 4 non-overlapping cohorts showed a strong association with 
survival which was consistent with the results of the 6 excluded studies. The results 
support the recent consensus statement from the Pediatric Task Force of the 5th World 
Symposium for Pulmonary Hypertension (WSPH) held in Nice 2013, which proposes 
to strive for WHO-FC I or II as a treatment goal in pediatric PAH.33 Treatment-induced 
changes in WHO-FC carry prognostic value in both adults and children, which further 
underscores its usefulness and validity as a pediatric treatment goal.34-36
(NT-pro)BNP. Pediatric studies that evaluated the prognostic value of (NT-pro)BNP 
differed regarding the biomarker under study (BNP, NT-proBNP or both), the used cut-off 
values and the analysis techniques. Nevertheless, there was a high degree of consis-
tency and a strong association with survival in the combined meta-analysis. A sensitivity 
analysis with solely inclusion of studies that studied BNP, also showed a significant as-
sociation with survival. It has recently been shown that children who stay on NT-proBNP 
levels below 1200 ng/L during treatment have significantly better survival rates, which 
is in line with adult findings regarding this topic.34,36 This suggests that a low NT-proBNP 
level is not only a strong predictor of survival, but is also a valid treatment goal to be 
used in pediatric goal-oriented treatment strategies.
Hemodynamic variables. Cardiac catheterization in childhood often requires seda-
tion or general anesthesia and has been reported to be accompanied by a complication 
rate of 4-6%.37 However, the fact that 4 of the 6 identified prognostic factors in this study 
are hemodynamic measures underlines the importance of cardiac catheterization, at 
least to assess disease severity and prognosis at time of diagnosis.
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Prognostic factors with low level of evidence
Although not statistically significant, APAH appeared to have a slightly more favorable 
prognosis compared to IPAH. Importantly, it must be noted that the meta-analysis 
concerning diagnosis was based upon HRs that were predominantly estimated from 
survival curves using Parmar’s survival curve method.10,38 This method is known to lead 
to underestimations of the HRs in smaller sample sizes, which subsequently could have 
led to an underestimation of the combined HR.39 In addition, all subtypes of APAH were 
analyzed together, while differences in prognostic value might exist within this group.
Other biomarkers than (NT-pro)BNP have also been shown to correlate with 
survival in pediatric PAH. The current systematic literature search showed that uric acid 
was a significant prognostic factor in 3 separate studies based on 2 non-overlapping 
cohorts (Table 2). Although uric acid was not frequently enough studied to be combined 
in meta-analysis, this indicates at least a low level of evidence for this prognostic factor.
Although meta-analysis could not be performed for echocardiography, this im-
aging modality has repeatedly been shown to yield important measures for prognosis 
(Table 2). Echocardiography is a generally accessible follow-up tool without the need 
for sedation or anesthesia and its role in assessing prognosis is already well established 
in adults.40 Five pediatric studies showed echocardiographic variables to be associated 
with survival (Table 2), which makes this modality a promising tool in managing pedi-
atric PAH. Further research is needed to enhance the body of evidence regarding these 
prognostic factors with low level of evidence.
Potential prognostic factors requiring further study
Other variables that were reported not sufficiently frequent to be meta-analyzed but 
may be potential prognostic factors include heart rate, blood pressure, height and 
weight, body surface area, heart rate variability, peak oxygen consumption, ventilatory-
efficiency slope, genetic mutations, hemoglobin, norepinephrine, Apolipoprotein-A-1, 
metallopeptidase-inhibitor-1 and soluble ST2 (Table 2). Future research should reveal 
which role these variables could play in assessing prognosis in pediatric PAH.
The prognostic value of CMR has only been studied incidentally in children and 
the accessibility to required infrastructure and expertise may not be widely available.41 
However, the well-established role of CMR in adults makes this a promising future imag-
ing modality in addition to echocardiography also in pediatric PAH.42
Of special future interest in relation to survival are measures of pulmonary artery 
capacitance, pulmonary artery distensibility, RV stroke work, and ventricular-vascular 
coupling, which to date have only been studied incidentally and anecdotally in relatively 
small cohorts.11,18,43-45The feasibility and potential prognostic value of combining imag-
ing modalities and cardiac catheterization are also under study and are expected to 
yield valuable insights in pulmonary arterial wall dynamics.44
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strengths and limitations
This recapitulation of published evidence for prognostic factors in pediatric PAH pro-
vides a unique clinical overview. Combining only randomized controlled trials would 
have been the most ideal way to identify prognostic factors. However, such trials report-
ing on prognostic factors are unavailable in this field. This could have led to a certain 
degree of heterogeneity, which was addressed in the current study by combining only 
studies with similar methodologies and providing a detailed description of the study 
characteristics (Table 1). Heterogeneity was tested for every meta-analyzed candidate 
prognostic factor, and revealed no substantial heterogeneity-evidence for the six identi-
fied statistically significant prognostic factors.
When HRs were not available, these were estimated using Parmar’s survival 
curve method, which is known to lead to underestimations of the hazard ratios in 
smaller sample sizes.39 HRs of statistically insignificant associations were sometimes not 
reported and could in those cases not be included in meta-analysis. Since this could 
potentially have led to an overrepresentation of significant results in the combined HR, 
these excluded studies are shown in tabular form to avoid bias within the current paper 
(Table 2).
We aimed to prevent duplicate patient representation in the meta-analyses. This 
was accomplished by restricting study inclusion to non-overlapping cohorts. Overlap 
was suspected in case of overlapping inclusion periods in studies performed at the 
same center. Although conservative and accompanied by the risk of also excluding non-
overlapping patients, this method ensured a pure and unbiased combined HR.
Considerations regarding future research
This study demonstrates the usefulness of the currently available literature on pediatric 
PAH. Nevertheless, available data are limited by relatively small sample sizes, insuf-
ficiently explained discrepancies and inevitable potential duplicate patient inclusion. 
Current international collaborative initiatives aim to overcome these limitations. The 
ongoing Tracking Outcomes and Practice in Pediatric PH (TOPP) registry encompasses 
the largest cohort of children with PAH to date and is expected to yield important new 
insights in survival and prognostic factors in pediatric PAH.46 Although a powerful tool 
with regard to sample size, the usefulness of any registry depends on the predefined 
aims and might be hampered by the fact that frequency and mode of follow-up are 
often not dictated.47
To be able to further investigate reported discrepancies and to increase sample 
size and statistical power, it could also be considered to merge existing patient cohorts 
on an individual patient level. Recently, a direct comparison has been made between 
three major pediatric PAH referral centers, which allowed for analyzing differences in 
survival rates between centers.4 Such initiatives could be further expanded in the future. 
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To provide transparency in the degree of duplicate patient inclusion throughout differ-
ent reports, it could be considered to publish lists of unique patient codes with every 
paper.
To be able to identify which prognostic factors could also qualify in defining 
treatment goals, future research should also focus on assessing the prognostic value of 
treatment-induced changes in these variables.34,48
ConClusIons
This systematic review combined with separate meta-analyses shows that WHO-FC, 
(NT-pro)BNP, mRAP, PVRi, cardiac index and acute vasodilator response are consistently 
reported prognostic factors in pediatric PAH. These variables are validated and useful 
clinical tools to assess prognosis. The current recapitulation of scientific evidence will 
provide an important basis for defining treatment strategies and developing practice 
guidelines for children with PAH. This systematic review does not preclude the potential 
of the other reported candidate prognostic factors, but rather identifies directions for 
further research to address gaps in current evidence.
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HR of high compared to low BNP 
Nakayma 2007, n=27 (400 pg/mL) 
Bernus 2009, n=78 (180 pg/mL) 
Lammers 2009, n=50 (130 pg/mL) 
COMBINED, n=155 (p=0.001) 
Heterogeneity: p=0.284, I2=20.5% 
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supplementary Figure 1. Forest plot showing combined prognostic value of brain natriuretic peptide. 
Area of each diamond ◆ is proportional to the sample size of the studied cohort. a HRs are estimated from 
survival curve. Between brackets are the cut-off values used in dichotomizing BNP. BNP = brain natriuretic 
peptide; HR = hazard ratio; CI = confidence interval.
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supplementary table 2. Studies Included During Full Text Review
First author Abbreviated Journal Title Year Study Site N Inclusion period
Sandoval [1] J Am CollCardiol 1995 Mexico City 18 1977 - 1991
Clabby [2] J Am CollCardiol 1997 US multicenter 50 1982 - 1992
Barst [3] Circulation 1999 New York 77 1982 - 1995
Yung [4] Circulation 2004 New York 44 1982 - 1995
Nakayama [5] Circ J 2007 Tokyo 31 1999 - 2004
Van Albada [6] Pediatr Res 2008 Netherlands 29 1997 - 2005
Bernus [7] Chest 2009 Denver 78 2005 - 2008
Haworth [8] Heart 2009 London 216 2001 - 2006
Lammers [9] Int J Cardiol 2009 London 50 2004 - 2006
Van Loon [10] Am J Cardiol 2010 Netherlands 52 1993 - 2008
Lammers [11] Int J Cardiol 2010 London 47 Not reported
Alkon [12] Am J Cardiol 2010 Toronto 47 1999 - 2008
Moledina [13] Heart 2010 London 64 2001 - 2007
Ivy [14] Am J Cardiol 2010 NY and Denver 86 2001 - 2003
Hislop [15] EurRespir J 2011 London 101 2002 - 2008
Moledina [16] Heart 2011 London 31 2007 - 2009
Sajan [17] Am Heart J 2011 Toronto 47 1996 - 2007
Van Loon [18] Circulation 2011 Netherlands 154 1991 - 2006
Barst [19] Circulation 2012 US multicenter 216 2006 - 2009
Chida [20] Am J Cardiol 2012 Japan/China multicenter 54 1995 - 2011
Apitz [21] J Am CollCardiol 2012 Giessen 43 Not reported
Douwes [22] Int J Cardiol 2013 Netherlands 52 1993 - 2010
Moledina [23] CircCardiovasc Imaging 2013 London 100 2007 - 2012
Kassem [24] Am Heart J 2013 Toronto 54 2004 - 2011
Wagner [25] Plos One 2013 Denver 83 2001 - 2008
Chida [26] Circ J 2014 Tokyo 59 Not reported
Zijlstra [27] J Am Coll Cardiol 2014 NL+Denver+NY 275 2000 - 2010
Citations are listed in Supplementary References section. US = United States; NL = Netherlands.
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supplementary table 3. Studies Excluded During Full Text Review
First author Abbreviated Journal Title Year Reason for exclusion
Houde [28] Br Heart J 1993 PAH not main topic
Kerstein [29] Circulation 1995 No survival analysis performeda
Darlow [30] N Z Med J 1998 PAH not main topic
Rosenzweig [31] Circulation 1999 No survival analysis performeda
Manzar [32] J Coll Physicians Surg Pak 2004 PAH not main topic
Humpl [33] Circulation 2005 No survival analysis performeda
Rosenzweig [34] J Am CollCardiol 2005 Endpoint other than Dt or Dt/LTx
Simpson [35] J Heart Lung Transplant 2006 No survival analysis performeda
Lammers [36] Heart 2007 No survival analysis performeda
Duffels [37] Int J Cardiol 2007 Analysis not restricted to children
Taylor [38] Br J Anaesth 2007 No survival analysis performeda
Van Loon [39] Am Heart J 2007 Analysis not restricted to children
Fasnacht [40] Swiss Med Wkly 2007 No survival analysis performeda
Joshi [41] Perinatology 2007 PAH not main topic
Ivy [42] J Am CollCardiol 2008 No survival analysis performeda
Kim [43] Korean Circ J 2008 No survival analysis performeda
Dickinson [44] J Heart Lung Transplant 2009 Analysis not restricted to children
Fraisse [45] Arch Cardiovasc Dis 2010 No survival analysis performeda
Barst [46] PediatrCardiol 2010 No survival analysis performeda
Melnick [47] Am J Cardiol 2010 No survival analysis performeda
Goldstein [48] J Heart Lung Transplant 2011 PAH not main topic
Schaellibaum [49] PediatrPulmonol 2011 PAH not main topic
Douwes [50] Eur Heart J 2011 Analysis not restricted to children
Takatsuki [51] PediatrCardiol 2012 No survival analysis performeda
Yeager [52] Proteomics ClinAppl 2012 No survival analysis performeda
Baruteau [53] Ann ThoracSurg 2012 No survival analysis performeda
Takatsuki [54] J Pediatr 2012 Endpoint other than Dt or Dt/LTx
Krishnan [55] Am J Cardiol 2012 No described survival
Duncan [56] Mediators Inflamm 2012 No survival analysis performeda
Siehr [57] J Heart Lung Transplant 2013 No survival analysis performeda
Kömhoff [58] Pediatrics 2013 No survival analysis performeda
Roofthooft [59] Am J Cardiol 2013 Endpoint other than Dt or Dt/LTx
Rausch [60] Int J Cardiol 2013 No survival analysis performeda
Maxey [61] PediatrCardiol 2013 No survival analysis performeda
Aiello [62] PediatrPulmonol 2014 No survival analysis performeda
Douwes [63] Heart 2014 No survival analysis performeda
Waruingi [64] World J Pediatr 2014 No survival analysis performeda
Barst [65] Circulation 2014 No survival analysis performeda
Citations are listed in Supplementary References section.a Survival analysis in which a candidate prognostic fac-
tor is evaluated using Cox regression analysis or Kaplan Meier analysis (not: comparison of treatment group 
survival). Dt = death; Dt/Ltx = death or lung-transplantation.
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